PMC:7784786 / 493-716 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":25,"end":30},"obj":"Gene"},{"id":"26","span":{"begin":32,"end":36},"obj":"Gene"},{"id":"27","span":{"begin":41,"end":46},"obj":"Gene"},{"id":"30","span":{"begin":120,"end":128},"obj":"Species"},{"id":"34","span":{"begin":142,"end":152},"obj":"Chemical"},{"id":"35","span":{"begin":193,"end":203},"obj":"Chemical"},{"id":"38","span":{"begin":96,"end":110},"obj":"Disease"},{"id":"39","span":{"begin":111,"end":119},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Gene:3458"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Gene:3569"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Gene:7124"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Tax:9606"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:C000597346"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:C000597346"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:D016638"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"kines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce "}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":48,"end":192},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"kines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce "}